Resumen

Objective: To assess the effect of exenatide twice daily according to different meal schedules on glycemic control and variability in patients with type 2 diabetes mellitus. Materials and methods: A randomized, open clinical trial was performed in 18 adults with type 2 diabetes mellitus who were overweight or obesity and inadequate glycemic control with metformin as monotherapy. Fasting glucose was < 12 mmol/l and glycated hemoglobin A1c between 7-9%. All patients received exenatide (5 ìg twice daily) subcutaneously for four weeks and continued taking metformin at the same dose throughout the study. A randomized distribution of six subjects was conducted to each of the following pre-prandial times of application of exenatide: (i) breakfast and lunch, (ii) breakfast and dinner, or (iii) lunch and dinner. At the beginning and four weeks later, glucose concentrations were measured every hour during a 24-hour period. Area under the curve of glucose and glycemic variability according to the mean amplitude of glycemic excursions was calculated. Results: Exenatide administration before breakfast and lunch significantly decreased fasting glucose and area under the curve of glucose after the intervention. The mean amplitude of glycemic excursions was similar in the three groups. Conclusions: Exenatide before breakfast and lunch appears to achieve better glycemic control.

Palabras clave: Exenatida glycemic variability glycemic control type 2 diabetes mellitus

2017-05-23   |   272 visitas   |   Evalua este artículo 0 valoraciones

Vol. 3 Núm.3. Julio-Septiembre 2016 Pags. 129-136 Rev Mex Endocrinol Metabol Nut 2016; 3(3)